Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer

NCT07049133 · clinicaltrials.gov ↗

RECRUITING

Status

84

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

OTHER: T-DXd toxicity marker identification

Sponsor

European Institute of Oncology